These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31546120)

  • 1. Characteristics and circumstances of death related to new psychoactive stimulants and hallucinogens in Australia.
    Darke S; Duflou J; Peacock A; Farrell M; Lappin J
    Drug Alcohol Depend; 2019 Nov; 204():107556. PubMed ID: 31546120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and circumstances of death related to buprenorphine toxicity in Australia.
    Darke S; Duflou J; Larance B; Farrell M; Lappin J
    Drug Alcohol Depend; 2021 Jan; 218():108360. PubMed ID: 33268226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A descriptive coronial study of heroin toxicity deaths in Australia, 2020-2022: Characteristics, toxicology and survival times.
    Darke S; Duflou J; Peacock A; Farrell M; Lappin J
    Addiction; 2024 Mar; 119(3):559-569. PubMed ID: 37921084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and concentrations of new designer stimulants, synthetic opioids, benzodiazepines, and hallucinogens in postmortem hair samples: A 13-year retrospective study.
    Niebel A; Westendorf L; Krumbiegel F; Hartwig S; Parr MK; Tsokos M
    Drug Test Anal; 2022 Jan; 14(1):110-121. PubMed ID: 34435749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and circumstances of death related to the self-administration of ketamine.
    Darke S; Duflou J; Farrell M; Peacock A; Lappin J
    Addiction; 2021 Feb; 116(2):339-345. PubMed ID: 32533718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and circumstances of synthetic cannabinoid-related death.
    Darke S; Duflou J; Farrell M; Peacock A; Lappin J
    Clin Toxicol (Phila); 2020 May; 58(5):368-374. PubMed ID: 31389266
    [No Abstract]   [Full Text] [Related]  

  • 7. Characteristics and circumstances of death related to gamma hydroxybutyrate (GHB).
    Darke S; Peacock A; Duflou J; Farrell M; Lappin J
    Clin Toxicol (Phila); 2020 Nov; 58(11):1028-1033. PubMed ID: 32068430
    [No Abstract]   [Full Text] [Related]  

  • 8. Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology.
    Kaye S; Darke S; Duflou J; McKetin R
    Addiction; 2008 Aug; 103(8):1353-60. PubMed ID: 18855825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2C or not 2C: phenethylamine designer drug review.
    Dean BV; Stellpflug SJ; Burnett AM; Engebretsen KM
    J Med Toxicol; 2013 Jun; 9(2):172-8. PubMed ID: 23494844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics.
    Rudin D; Liechti ME; Luethi D
    Exp Neurol; 2021 Sep; 343():113778. PubMed ID: 34090893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of fatal 'novel' benzodiazepine toxicity in Australia.
    Darke S; Peacock A; Duflou J; Farrell M; Lappin J
    Forensic Sci Int; 2022 Feb; 331():111140. PubMed ID: 34894611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.
    Liechti M
    Swiss Med Wkly; 2015; 145():w14043. PubMed ID: 25588018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances.
    Matthews A; Sutherland R; Peacock A; Van Buskirk J; Whittaker E; Burns L; Bruno R
    Int J Drug Policy; 2017 Feb; 40():44-49. PubMed ID: 27939599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel psychoactive substances: the pharmacology of stimulants and hallucinogens.
    Schifano F; Papanti GD; Orsolini L; Corkery JM
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):943-54. PubMed ID: 26985969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylenedioxymethamphetamine (MDMA)-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology.
    Kaye S; Darke S; Duflou J
    Drug Alcohol Depend; 2009 Oct; 104(3):254-61. PubMed ID: 19604654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in neuronal activity in rat primary cortical cultures induced by illicit drugs and new psychoactive substances (NPS) following prolonged exposure and washout to mimic human exposure scenarios.
    Zwartsen A; Hondebrink L; Westerink RH
    Neurotoxicology; 2019 Sep; 74():28-39. PubMed ID: 31078573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designer drugs: mechanism of action and adverse effects.
    Luethi D; Liechti ME
    Arch Toxicol; 2020 Apr; 94(4):1085-1133. PubMed ID: 32249347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of synthetic stimulants and hallucinogens in a cohort of electronic dance music festival attendees.
    Mohr ALA; Friscia M; Yeakel JK; Logan BK
    Forensic Sci Int; 2018 Jan; 282():168-178. PubMed ID: 29216523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates, characteristics and circumstances of methamphetamine-related death in Australia: a national 7-year study.
    Darke S; Kaye S; Duflou J
    Addiction; 2017 Dec; 112(12):2191-2201. PubMed ID: 28603836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 3-year review of new psychoactive substances in casework.
    Elliott S; Evans J
    Forensic Sci Int; 2014 Oct; 243():55-60. PubMed ID: 24810679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.